Citigroup Inc Lyra Therapeutics, Inc. Transaction History
Citigroup Inc
- $163 Billion
- Q4 2024
A detailed history of Citigroup Inc transactions in Lyra Therapeutics, Inc. stock. As of the latest transaction made, Citigroup Inc holds 38,102 shares of LYRA stock, worth $4,191. This represents 0.0% of its overall portfolio holdings.
Number of Shares
38,102
Previous 35,036
8.75%
Holding current value
$4,191
Previous $9,000
11.11%
% of portfolio
0.0%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding LYRA
# of Institutions
54Shares Held
26.2MCall Options Held
21KPut Options Held
0-
Perceptive Advisors LLC New York, NY12.8MShares$1.4 Million0.09% of portfolio
-
Black Rock Inc. New York, NY2.83MShares$311,2970.0% of portfolio
-
Samsara Bio Capital, LLC Palo Alto, CA1.97MShares$216,2250.13% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.79MShares$196,6160.0% of portfolio
-
Ikarian Capital, LLC Dallas, TX1.06MShares$116,3960.04% of portfolio
About Lyra Therapeutics, Inc.
- Ticker LYRA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 31,826,400
- Market Cap $3.5M
- Description
- Lyra Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained...